1. "Myeloma"
Formats
  1. Meeting Abstract (543)
  2. Journal Article (358)
  3. Review (36)
  4. Research Letter (19)
  5. Book Section (10)
  6. Guidelines (10)
  7. Correspondence (6)
  8. Editorial (5)
  9. Conference Paper (1)
Groups
  1. Center for Hematologic Malignancies (988)
  2. Department of Medicine (988)
  3. Hematologic Malignancies, Division of (988)
  4. Myeloma (988)
  5. Hematologic Malignancies Research (651)
  6. Survivorship Research (356)

More Groups

People
  1. Alexander Lesokhin (363)
  2. Carl Landgren (336)
  3. Hani Hassoun (329)
  4. Sham Mailankody (282)
  5. Malin Hultcrantz (260)
  6. Heather Landau (239)

More People

Years
  1. 2025 (13)
  2. 2024 (69)
  3. 2023 (115)
  4. 2022 (96)
  5. 2021 (76)
  6. 2020 (95)

More Years

Publications
  1. Blood (303)
  2. Clinical Lymphoma, Myeloma and Leukemia (96)
  3. Journal of Clinical Oncology (85)
  4. Haematologica (41)
  5. Biology of Blood and Marrow Transplantation (29)
  6. Blood Cancer Journal (22)

More Publications

Publishers
  1. American Society of Hematology (324)
  2. Elsevier Inc. (159)
  3. American Society of Clinical Oncology (87)
  4. Nature Publishing Group (83)
  5. Ferrata Storti Foundation (41)
  6. American Association for Cancer Research (34)

More Publishers

Results (988)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) - health-related quality of life (HRQoL) analysis
    Meeting Abstract

    Oriol, A.; Richardson, P. G.; Mateos, M. V.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Rodríguez-Otero, P.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Infusion-related reactions (IRRs) in the DREAMM-2 Study of single-agent belantamab mafodotin (belamaf) in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nooka, A.; Lee, H. C.; Badros, A. Z.; Voorhees, P.; Hultcrantz, M.; Karlin, L.; Arnulf, B.; Richardson, P. G.; Zhi, E.; Baron, J.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Whole-genome sequencing reveals evidence of two biologically and clinically distinct entities: Progressive versus stable myeloma precursor disease
    Meeting Abstract

    Oben, B.; Froyen, G.; Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Abascal, F.; Leongamornlert, D. A.; Derkach, A.; Geerdens, E.; Diamond, B.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)-analysis of adverse events related to hospitalizations
    Meeting Abstract

    Nadeem, O.; Richardson, P. G.; Mateos, M. V.; Oriol, A.; Larocca, A.; Creixenti, J. B.; Rodríguez-Otero, P.; Leleu, X.; Norkin, M.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma with high-risk cytogenetics-subgroup analysis
    Meeting Abstract

    Mateos, M. V.; Oriol, A.; Larocca, A.; Creixenti, J. B.; Cavo, M.; Rodríguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Universal: An allogeneic first-in-human study of the anti-BCMA ALLO-715 and the anti-CD52 ALLO-647 in relapsed/refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Matous, J. V.; Liedtke, M.; Sidana, S.; Malik, S.; Nath, R.; Oluwole, O. O.; Karski, E. E.; Lovelace, W.; Zhou, X.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • CARTITUDE-1: Phase 1b/2 study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in relapsed/refractory multiple myeloma
    Meeting Abstract

    Madduri, D.; Berdeja, J. G.; Usmani, S. Z.; Jakubowiak, A.; Agha, M.; Cohen, A. D.; Stewart, A. K.; Hari, P.; Htut, M.; O'Donnell, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Copy number signatures predict chromothripsis and poor clinical outcome in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Derkach, A.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • The genomic complexity of multiple myeloma precursor disease can be predicted using copy number signatures on targeted sequencing and SNP array data
    Meeting Abstract

    Maclachlan, K. H.; Zheng-Lin, B.; Yellapantula, V.; Rustad, E. H.; Diamond, B.; Hultcrantz, M.; Dogan, A.; Zhang, Y.; Morgan, G.; Landgren, O.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • HORIZON (OP-106): Melflufen plus dexamethasone in patients with relapsed/refractory multiple myeloma-age subgroup analysis of elderly patients
    Meeting Abstract

    Larocca, A.; Richardson, P. G.; Oriol, A.; Creixenti, J. B.; Cavo, M.; Rodríguez-Otero, P.; Leleu, X.; Norkin, M.; Nadeem, O.; Hiemenz, J. W.; more...
    Blood (2020)

    Fulltext@MSK | Save